Nabet Lab
Our Research
One of the hallmarks of cancer is deregulation of signal transduction – cancer cells are experts in rewiring proteomic, transcriptional, and epigenetic networks to drive cell growth and survival. While these pathways identify targetable vulnerabilities in cancer, there remains a shortage of targeted agents that disrupt critical signaling nodes and/or overcome drug resistance. The Nabet lab is dedicated to targeting oncogenic signaling networks through control of protein homeostasis to advance new therapeutic strategies in cancer.
Featured Publications
ChemBioChem
Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity.
Koide E, Mohardt ML, Doctor ZM, Yang A, Hao M, Donovan KA, Kuismi CC, Nelson AJ, Abell K, Aguiar M, Che J, Stokes MP, Zhang T, Aguirre AJ, Fischer ES, Gray NS, Jiang B#, Nabet B#. (2023).
Nature Communications
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.
Nabet B*,#, Ferguson FM*, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, Robichaud A, Conway AS, Buckley DL, Mancias JD, Bradner JE, Stegmaier K, Gray NS#. (2020).
Nature Chemical Biology
The dTAG system for immediate and target-specific protein degradation.
Nabet B*, Roberts JM*, Buckley DL*, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong K-KK, Gray NS, Bradner JE. (2018).
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.